Financial News
Articles published by Arrowhead Pharmaceuticals, Inc.
![](https://mms.businesswire.com/media/20231106125688/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
November 06, 2023
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20231102177363/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
November 02, 2023
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20231003514931/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230927237130/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 27, 2023
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230911960460/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
September 11, 2023
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230901266309/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230807767868/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230717943170/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20230706609231/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 06, 2023
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230627815548/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20230624840872/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20230606005382/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230601005471/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230515005688/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230502006103/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230425005446/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20230418005343/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230412005207/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230404005248/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20230331005058/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 31, 2023
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230320005270/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
March 20, 2023
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230303005032/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230228005667/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20230206005572/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
February 06, 2023
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20230125005249/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20221221005061/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20221220005204/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20221215006007/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 15, 2022
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20221208005287/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
December 08, 2022
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20221128005710/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
November 28, 2022
Via Business Wire
Tickers
ARWR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.